PHARMAC performance 2018/19 Q3
Performance data to 31 March 2019
Output Class 1: Decision-making
Measure: Savings are made to meet the cost of future growth and allow for new investments.
Status: On track. Savings are generated to meet the cost of future volume growth and allow for new investments. This financial year PHARMAC has listed 10 new medicines and expanded access to 10 more, at a gross cost of $114.4 million, from within the available budget.
Measure: The total value and number of hospital medical devices under contract increases.
Status: On track. Expenditure under contract increased by around $15-20 million. We listed 9,322 new medical devices this quarter. The total number of medical devices listed is now 87,000.
Output Class 2: Influencing medicines use
Measure: DHB hospital engagement with PHARMAC compared with previous year.
Status: Meetings have been held with all DHBs who currently use cardiac drug eluting stents to support any potential change to the market with these products. Four focus groups were held with DHB representatives to gain feedback to help shape the medical devices consultation materials and look and feel. Planning is underway for consultation opening in March 2019.
Measure: Survey of attendants at a PHARMAC Seminar show a positive professional change in optimal use behaviour as a result of attendance.
Status: On track. Nine PHARMAC seminars were held between July and December 2018. Surveys to assess change are sent 2 – 3 months after Seminars, so five behaviour change surveys have been completed. Eighty per cent of respondents to the survey have made positive changes as a result of attendance at a seminar.
Measure: Medicines use community health programmes are delivered to a range of health and community workers.
Status: On track. Planning for community-based delivery of programmes has occurred in over half of all our Whānau Ora Collective (WOC) partner areas for Quarter 2. The number of WOC partners has increased by one.
Measure: Low medicine stock situations are identified and managed so that there are no clinically meaningful consequences to patients.
Status: On track. PHARMAC has worked with suppliers to identify, monitor and manage all low medicine stock reports.
Output Class 3: Providing policy advice and support
Measure: PHARMAC staff participate in and contribute to wider sector forums.
Status: On track. PHARMAC continues to actively instigate and participate in various engagements across the health sector.
Measure: All rebates are collected and distributed to DHBs in accordance with PHARMAC policy.
Status: On track. All PHARMAC fund use is in accordance with PHARMAC policy.
Last updated: 8 May 2019